Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.

"Conflict of interest The work described in this analysis was supported by Bayer Pharma AG. The funding organization was given an opportunity to comment on a draft manuscript before submission. However, the authors had the ultimate responsibility for materials included in the final submitted manuscript. M.P.C., C.D.P., and C.J.C. hold no financial interests or share holdings in the sponsoring organization. J.C. is an employee at Bayer HealthCare, Whippany, NJ, USA."

"We thank the patients and their families, the GRID study investigators, and the staff at each of the participating study centers. The GRID trial was sponsored by Bayer HealthCare Pharmaceuticals and is registered on clinicaltrials.gov as NCT01271712. Conflict of interestThe work described in this analysis was supported by Bayer Pharma AG. The funding organization was given an opportunity to comment on a draft manuscript before submission. However, the authors had the ultimate responsibility for materials included in the final submitted manuscript. M.P.C., C.D.P., and C.J.C. hold no financial interests or share holdings in the sponsoring organization. J.C. is an employee at Bayer HealthCare, Whippany, NJ, USA."

"We thank the patients and their families, the GRID study investigators, and the staff at each of the participating study centers. The GRID trial was sponsored by Bayer HealthCare Pharmaceuticals and is registered on clinicaltrials.gov as NCT01271712."